379679-70-6

Upstream product

• 5870-62-2 3-hydroxy-2-cyclopenten-1-one 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 3859-41-4 1,3-cyclopentadione 
• 352-33-0 1-Chloro-4-fluorobenzene 
• 379679-62-6 3-bromo-2-(4-fluorophenyl)-2-cyclopenten-1-one 
• 1765-93-1 4-fluoroboronic acid 
• 379679-67-1 3-methoxy-2-(4-fluorophenyl)-2-cyclopenten-1-one 

Downstream Products

• 190269-78-4 (1R,2R,3S)-2-(4-fluorophenyl)-3-hydroxycyclopentane-1-carboxylic acid 
• 960364-46-9 C₄₁H₃₆F₇NO₆ 
• 871589-73-0 ((1S),(2R),(3R))-1-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)-3-((1R)-1-(benzyloxycarbonylamino)pent-4-en-1-yl)cyclopentane 
• 871589-72-9 ((1S),(2R),(3R))-1-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)-3-((1S)-1-(benzyloxycarbonylamino)pent-4-en-1-yl)cyclopentane 
• 871589-69-4 C₂₆H₂₈F₇NO 
• 871589-84-3 (3R,5R)-5-(((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentan-1-yl)-1,3-dibenzyloxycarbonyl-3-methylpyrrolidin-2-one 
• 871589-85-4 (3R,5R)-5-(((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentan-1-yl)-3-carboxy-3-methylpyrrolidin-2-one 
• 871589-71-8 ((1S),(2R),(3R))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-2-(4-fluorophenyl)-3-(1-oxopent-4-en-1-yl)cyclopentane 
• 405512-89-2 ((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentanecarboxaldehyde 

Relevant academic research and scientific papers

COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE

This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and an anti-muscarinic agent or a pha

Lactam tachykinin receptor antagonists

The present invention is directed to certain lactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations compri

Asymmetric synthesis of 1,2,3-trisubstituted cyclopentanes and cyclohexanes as key components of substance P antagonists

An efficient asymmetric synthesis of 1,2,3-trisubstituted cyclopentanes and cyclohexanes is described. Three methods were developed for the preparation of the 2,3-disubstituted cyclopentenones and cyclohexenones, which are key achiral building blocks. These intermediates are reduced catalytically with (R)-2-methyloxazaborolidine in high yield (82-98%) and excellent ee (89-96%). Directed reduction of the chiral allylic alcohols using Red-Al gives exclusively the 1,2-anti stereochemistry (>99:1). Epimerization of the ester center followed by saponification/crystallization affords the desired hydroxyacids in good yield (65-70%) and in high enantiomeric excess (>99%).